Imbruvica and Its Impact on Patients - WuXi XPress: for WuXi news and R&D insights
Patient Resources & Information for IMBRUVICA® (ibrutinib)
Imbruvica 560 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc)
New Drug Product: IMBRUVICA - MPR
Janssen Seeks Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL) | Business Wire
Imbruvica (ibrutinib) FDA Package Insert & Drug Facts - Iodine.com
Imbruvica (Ibrutinib) for the Treatment of Mantle Cell Lymphoma (MCL) - Clinical Trials Arena
These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA. IMBRUVICA ® (ibrutinib) capsules, for oral use IMBRUVICA ® (ibrutinib) tablets,
FDA expands Imbruvica's label to include survival data - PharmaTimes
AbbVie's Imbruvica Expected to Become a Leading Oncology Drug
AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks | FiercePharma
MCL - Study 1104 Study Design for R/R MCL | IMBRUVICA® (ibrutinib)
Supplemental Materials for Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study - The Lancet Oncology
J&J pushes to expand Imbruvica label after clinical success - PMLiVE
These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA. IMBRUVICA ® (ibrutinib) capsules, for oral use IMBRUVICA ® (ibrutinib) tablets,
NICE approves Imbruvica for second-line leukaemia treatment | Pharmafile
BeiGene's Phase III Waldenström's study misses mark, but with a possible silver lining - MedCity News
NDC 57962-070 Imbruvica Ibrutinib
BeiGene nabs landmark FDA nod for Brukinsa, kicking off challenge against blockbuster Imbruvica | FiercePharma
IMBRUVICA® (ibrutinib) - Cancer Therapy Advisor
These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA. IMBRUVICA ® (ibrutinib) capsules, for oral use IMBRUVICA ® (ibrutinib) tablets,
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial - The Lancet Oncology
Off-label Imbruvica Helped Ease CAD Symptoms, Preliminary Study Shows
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial - The Lancet Haematology
Pooled Analysis: Study Design | IMBRUVICA® (ibrutinib) | HCP
Imbruvica Full Prescribing Information, Dosage & Side Effects | MIMS Hong Kong
